Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms.
Condition(s) studied
Investigational drug(s) / intervention(s)
HIFU treatment in rectal Endometriosis: HIFU treatment of rectal endometriosis
SHAM HIFU procedure: SHAM HIFU procedure
Study summary
Rectal endometriosis (RE) induces lesions associated with painful symptoms that can alter quality of life. High Intensity Focused Ultrasound (HIFU) is a non-invasive ablative procedure using a high-intensity ultrasound probe to induce tissue devitalization using acoustic cavitation and thermal ablation.
Focal One® is a transrectal HIFU device, which is validated to treat prostatic cancer.
In this comparative, randomized, double blind study , the primary objective is to evaluate the efficacy of the HIFU treatment of rectal endometriosis with Focal One® HIFU device on the Acute Pelvic Pain 3 months after HIFU treatment, in comparison to a Sham group.
Eligibility
Primary outcome measure(s)
- Comparison of the evolution in the level of acute pelvic pain compared to the sham intervention group. — 3 months
The efficacy of HIFU treatment will be assessed by comparing the evolution in the level of acute pelvic pain assessed by Visual Analog Scale (VAS), ranging from 0 (best situation) to 10 (worst situation) at 3 months, to the pre-treatment pain level. The evolution in the HIFU group will be compared to those in the sham intervention group.
Trial sites (9)
| Facility | City | Region | Status |
|---|---|---|---|
| Hopital Privé de Provence | Aix-en-Provence | France | |
| CHU de Angers | Angers | France | |
| Clinique Tivoli-Ducos | Bordeaux | France | |
| Chu Estaing | Clermont-Ferrand | France | |
| Hôpital du Kremlin Bicetre | Le Kremlin-Bicêtre | France | |
| Hôpital privé Le Bois | Lille | France | |
| Hopital de la Croix Rousse | Lyon | France | |
| Hôpital COCHIN | Paris | France | |
| CHU Strasbourg | Strasbourg | France |
More EDAP TMS S.A. trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05755958 on ClinicalTrials.gov ↗ ← All trials in France